Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ALDR - Alder Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Alder Biopharmaceuticals Inc. is Fair to Shareholders; Investors Are Encouraged to Contact The Firm - ALDR


ALDR - Alder Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Alder Biopharmaceuticals Inc. is Fair to Shareholders; Investors Are Encouraged to Contact The Firm - ALDR

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) to H. Lundbeck A/S (“Lundbeck”) is fair to Alder shareholders. On behalf of Alder shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

If you are an Alder shareholder and would like to discuss your legal rights and options, please visit Alder BioPharmaceuticals Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Alder, whereby Alder stockholders will be offered an upfront payment of $18.00 per share in cash, along with one non-tradeable Contingent Value Right that entitles them to an additional $2.00 per share upon approval of eptinezumab by the European Medicines Agency. The Alder merger investigation concerns whether Alder and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Alder shareholders; (2) determine whether Lundbeck is underpaying for Alder; and (3) disclose all material information necessary for Alder shareholders to adequately assess and value the merger consideration.

If you are an Alder shareholder and would like to discuss your legal rights and options, please visit https://halpersadeh.com/actions/alder-biopharmaceuticals-inc-aldr-stock-merger-lundbeck/ or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060

sadeh@halpersadeh.com
zhalper@halpersadeh.com 
https://www.halpersadeh.com


Stock Information

Company Name: Alder BioPharmaceuticals Inc.
Stock Symbol: ALDR
Market: NASDAQ
Website: alderbio.com

Menu

ALDR ALDR Quote ALDR Short ALDR News ALDR Articles ALDR Message Board
Get ALDR Alerts

News, Short Squeeze, Breakout and More Instantly...